Actavis Group has announced the launch of Lercanidipine in five European countries. The drug is mainly used to treat high blood pressure.
The company launched the product under its own brand name on day one in the UK and France, where the patents expired on 20 and 21 January, respectively. The product was also launched on day one in France, the UK, the Netherlands, Belgium and Italy by clients of Medis, Actavis' Third-party sales division.
The drug will be launched in various other European countries as patents expire in the near future.
Share this: 
Del.icio.us |
